AG-270 以剂量依赖方式显著降低 HCT116 MTAP 缺失细胞中 SAM 的水平,同时在体外 HCT116 MTAP 同质性细胞模型中表现出 MTAP 缺失选择性的抗增殖活性 (IC50 为 20 nM; 72 小时)。MAT2A 是甲硫氨酸循环通路中的关键酶,负责生成通用甲基供体 S-腺苷甲硫氨酸 (SAM) ;AG-270 在各种物种(人类、小鼠、大鼠、狗和猴子)中均表现出优异的微粒体、肝细胞和体内代谢稳定性。AG-270 在小鼠、大鼠、猴子和狗中的 T1/2 值分别为 5.9 小时、4.2 小时、4.8 小时和 21.3 小时。AG-270 (200 mg/kg,每天一次,共38天)可导致KP4 MTAP缺陷异种移植瘤的肿瘤SAM水平和肿瘤生长呈剂量依赖性降低,且耐受性良好,平均体重减轻<5%。AG-270 与紫杉烷和吉西他滨联合使用产生了协同抗肿瘤活性,其中与多西他赛联合使用在选定模型中可使肿瘤完全消退 50%;在源自食道癌、NSCLC 和胰腺癌的 PDX 模型中观察到了联合治疗优势。
AG-270 demonstrates potent reduction in levels of intracellular SAM , as well as MTAP-–selective antiproliferative activity in the HCT116 MTAP isogenic cell model in vitro. AG-270 exhibits an IC 50 of 20 nM in HCT116 MTAP- cell SAM at 72 h. MAT2A is a key enzyme in the methionine salvage pathway, responsible for generating the universal methyl donor, S-adenosylmethionine (SAM). In Vivo:AG-270 shows excellent microsomal, hepatocyte, and in vivo metabolic stability across species (human, mouse, rat, dog, and monkey). AG-270 exhibits T1/2 values of 5.9 h, 4.2 h, 4.8 h and 21.3 h in mouse, rat, monkey and dog, respectively . AG-270 (200 mg/kg, orally, q.d. for 38 days) results in dose-dependent reduction in tumor SAM levels and tumor growth of KP4 MTAP- xenografts and is well tolerated, with mean body weight loss <5% . Combining AG-270 with taxanes and gemcitabine yielded additive-tosynergistic antitumor activity, with the docetaxel combination yielding 50% complete tumor regressions in select models; combination benefits are observed in PDX models derived from esophageal, NSCLC, and pancreatic cancers.